Project Grant R15AG085620
Award Date
8/15/24
Completion Date
7/31/27
Dollars Obligated
$454K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Boca Raton, FL 33431, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
This $200,323 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research by the University of South Florida to investigate the aggregation of amyloid-beta (Aβ) peptides during metabolic stress and spreading depolarization events in the brain. The project will utilize multiscale modeling, high-resolution microscopy, antibody staining, and paralysis phenotype testing in C. elegans to determine how physiochemical changes...
This Project Grant award of $295,000 from the National Institute on Aging (CFDA 93.866 Aging Research program) aims to develop biotherapeutic nanogels for the treatment of Alzheimer's disease (AD). The project will focus on improving the nanogels for enhanced blood-brain barrier transmigration and evaluating their efficacy in a mouse model of AD. Specifically, the nanogels are designed to target key AD biomarkers like amyloid-beta, tau, and neuroinflammation to ameliorate oxidative stress and...
This Project Grant award of $614,424 from the National Institute on Aging (CFDA 93.866 Aging Research program) supports research to illuminate early microglial dysfunction in Alzheimer's disease (AD). The study aims to integrate novel explainable AI techniques with deep learning methods to better define AD-specific microglial states and pathways from single-cell brain data. As proof-of-concept, the researchers will model the combined effects of AD stimuli and neuronal injury on...
This federal Project Grant award, valued at $972,000.00 and awarded by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to characterize the genetic architecture underlying the onset of amyloid positivity in Alzheimer's disease (AD). The principal investigator will leverage advanced imaging and genetic analysis techniques, including artificial intelligence, to estimate the age of amyloid-beta onset from over 16,000 positron emission tomography scans. This research seeks to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $433,125 will fund a study to investigate the relationship between microglia, neurons, and tau pathology in Alzheimer's disease. The research will utilize a novel model system of microglial co-cultures with hippocampal assembloids derived from patient-derived induced pluripotent stem cell (iPSC) lines with MAPT mutations and healthy controls. The goal is to explore how bidirectional changes...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Florida International University provides $479,375 in funding to investigate the effects of a small molecule activator of autophagy, TPI-132, on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease. The goal is to determine if modulating the autophagy-lysosome pathway through TPI-132 can increase neuroprotection, mitigate insulin resistance and senescence, and...
This $3,845,311 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund research at the University of California, San Diego (UCSD) to investigate early determinants of Alzheimer's disease (AD) using patient-derived induced neurons (iNs). The project aims to better understand the mechanisms that cause mild cognitive impairment (MCI) and the progression to AD, integrating multi-omic analysis of MCI patient-specific iNs with polygenic risk scores....
This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...